Review of guidelines on the treatment of metastatic renal cell carcinoma by Soulières, D.
GUIDELINES IN METASTATIC RCC
S67
Cu r r e n t On C O l O g y —VO l u m e  16, Su p p l e m e n t 1 Copyright © 2009 Multimed Inc.
Review of guidelines on 
the treatment of metastatic 
renal cell carcinoma
D. Soulières m d  m S c
primary endpoint, but also the secondary endpoints 
that should corroborate the primary endpoint, will stand. 
This approach is based on the Prentice principle, 
which states that a result has a higher probability of 
being truly positive if other related endpoints are also 
positive 1. An advantage in progression-free survival 
(p f s) has more chance of being true if a statistically 
significant advantage is also present for other aspects 
of efficacy such as response rate, time to treatment 
failure, and survival (if these data are available).
Remembering the Prentice principle, it will 
therefore be the prerogative of the editorial nature 
of the present paper to determine whether recom-
mendations present in more than one guideline are 
likely to have a potential to affect practice. This 
paper also tries to comment on the reasons for the 
selection of certain treatment options and whether 
previous recommendations based on older data still 
apply in view of the treatment options that have so 
drastically modified the prognosis and survival of 
patients with metastatic r c c .
2.  DISCUSSION
Recognizing the role of the von Hippel–Lindau gene 
product (v h l ) and its value as a target in r c c  has lent 
specific interest to this disease and to the controversy 
concerning which agent to use and when to use it 2. 
Moving from basically no efficacious therapy to 
several options also puts a strain on the deciders who 
have the responsibility to finance the new therapies 
to the best possible effect on an entire population of 
patients with r c c . Guidelines should therefore be as 
strong as possible and should reflect possibilities that 
have an effect not just on a selected trial population, 
but also on a general population. For example, the 
study conducted in British Columbia on all patients 
treated for r c c  demonstrated that the introduction of 
sunitinib therapy, as compared with interferon ther-
apy, for r c c  resulted in a doubling of overall sur-
vival (o s ) based on historical results 3. These data 
reinforce the validity of guidelines proposing the use 
of sunitinib for metastatic r c c  patients in the first line 
of therapy.
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1.  INTRODUCTION
Principles that apply, or should apply, to the develop-
ment of practice guidelines vary from one profes-
sional group to the next, based on their interpretation 
of the literature and on regional particularities that 
relate more to access to therapy than to applicability 
or true population differences. Therefore, a review of 
guidelines is per se an impossible endeavour, because 
it implies rendering judgment on an ensemble of 
processes that lead to a “best proposal” based on 
available data and current conditions.
Another impediment to a review of guidelines is 
the rapidity at which information regarding a par-
ticular pathology evolves. A magnitude of data with 
the potential to modify the practice of physicians 
caring for patients with metastatic renal cell carcinoma 
(r c c ) has emerged over the last few years, including 
data from several studies stopped prematurely at interim 
analysis because of positive results. The interpretation 
of those data therefore depends on the premises that 
final results will concord with early analyses and that 
the statistical strength of the analyses of not only the 
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Internationally recognized guidelines that were 
evaluated for the purpose of the present paper include 
those produced by the European Association of Urol-
ogy (e a u ), the U.S. National Comprehensive Cancer 
Network (n c c n ), and the Canadian Urological As-
sociation (c u a —specifically, the Canadian Kidney 
Cancer Forum) 4–6. The e a u  publication dates from 
2007, whereas the n c c n  guidelines were reviewed in 
January 2009. The published guidelines of the c u a  
were published in 2008, but a revision has been com-
pleted, and its major elements are reported here.
2.1  On Surgery
All guidelines refer to data concerning the positive 
effect of nephrectomy on survival in patients with 
metastatic disease. Although all guidelines recommend 
surgery, some propose it only for patients for whom 
interferon therapy is scheduled or intended. There-
fore, even though data pertaining to surgical therapy 
come from randomized trials, the systemic therapies 
in the comparator arms are not a standard that applies 
in 2009 7,8. Either restraining the applicability of 
surgery or questioning its validity or relevance for all 
patients is therefore adequate. The limited data on 
patients who did not undergo nephrectomy before a 
targeted systemic therapy was initiated do not seem 
to indicate a survival disadvantage. The data on the 
use of nephrectomy, a procedure with a potential for 
severe complications, should therefore be put into 
context and more fully studied, as is currently occur-
ring in a trial by a French collaborative group.
2.2  On Prognostic Factors
Most trials of investigational agents in the last few 
years have been conducted using a stratification based 
on prognostic factors developed by Motzer and col-
leagues using a population of patients starting therapy 
with interferon 9. The effect of prognostic factors is 
extremely dependent on the time of measurement of 
those factors. Only in post hoc analyses can it be deter-
mined if the prognostic value of the factors still applies. 
Although validation efforts, based on data from recent 
trials, do not seem to support retention of much prog-
nostic value for these prognostic factors, they have 
been used as a therapy selection criterion in all guide-
lines 10. Moreover, prognostic factors used for patient 
selection or stratification have varied from one study 
to another. This variation renders treatment selection 
based on biologic parameters and review of data more 
difficult, not to say a simple element of confusion.
Although data seem to indicate a variation in 
survival between poor-risk and other patients, the dif-
ference is not as significant as was initially reported 
by Motzer et al. based on their Memorial Sloan–Ket-
tering experience with interferon patients. In view of 
this fact, the Canadian guidelines have recently been 
modified to partly account for this realization—at least 
for first-line therapy. As stated earlier, if guidelines 
are followed adequately, they should lead to a change 
in population-based statistics, such as those reported 
by Heng et al. 3.
Incoherence in patient definitions, such as that 
created by the addition of information on factors with 
uncertain relevance in the era of targeted therapy, 
makes evaluation of a whole-population effect dif-
ficult and perhaps impossible, because full and com-
plete databases are not kept on all patients with r c c  
or other types of cancer. Definitions of cancer sub-
groups should therefore be based on tumour charac-
teristics that should be sought only after prospective 
data demonstrate an effect on the efficacy of new 
therapies (not unlike the development of trastuzumab 
in breast cancer positive for the human epidermal 
growth factor receptor). The principle is therefore 
moving away from prognostic factors that should be 
independent of treatment and toward the identification 
of factors predictive of response to therapy.
Another option in designing and tailoring therapy 
is to use nomograms 11, but the use of nomograms in 
daily practice is not fully recognized, and validations 
based on population studies—such as the one per-
formed by Heng and colleagues under Kollmanns-
berger—have not yet been reported.
2.3  On Anti-angiogenic Therapy
All guidelines state that sunitinib should be consid-
ered standard therapy in the first-line setting for 
metastatic r c c . The Canadian guidelines were re-
cently modified to include all comers without regard 
for risk factors, because all subgroups analyzed dem-
onstrated a benefit in terms of response and p f s. One 
element that strikes home in the analysis of guidelines 
and that probably led to these conclusions is the fact 
that sunitinib is the only vascular endothelial growth 
factor receptor (v e g f r ) tyrosine kinase inhibitor (t k i ) 
to be proposed in the first-line setting. In an attempt 
to demonstrate differences between that agent and 
sorafenib, the revision of the preferred surrogate 
markers of efficacy (that is, response rates) leads to 
the conclusion that the Prentice principle applies 
equally well to targeted therapy. Sunitinib demon-
strated higher response rates in all studies, and the 
only possible assumption is that that finding correlates 
with an advantage in p f s, and ultimately o s , as evi-
denced by multiple analyses of the phase iii trial and 
the paper by Heng et al. 3.
Tyrosine kinase inhibitors are not the only anti-
angiogenic therapy that has proven active in meta-
static r c c. A combination of bevacizumab and 
interferon is also accepted as an option in the guide-
lines, based on two trials that were reported prema-
turely because of an advantage in p f s. However, the 
primary endpoint of those trials was o s , and a sig-
nificant advantage there has not been reported at the 
time of writing. It therefore seems rather difficult to GUIDELINES IN METASTATIC RCC
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propose the bevacizumab and interferon combination 
as a standard in the first-line setting without formal 
evidence concerning the primary endpoint of the 
study. Moreover, important questions remain concern-
ing the validity of this combination as compared with 
bevacizumab alone over interferon. The paucity of 
preclinical data leads most clinicians to believe that 
the combination will probably lead to more side ef-
fects than benefit. In fact, in the av o r e n  [Avastin 
(Genentech, San Francisco, CA, U.S.A.) for Renal 
Cell Cancer] trial, the combination was less well 
tolerated than was interferon alone, whereas v e g f r -
t k i s are generally better tolerated than interferon is. 
Because all guidelines list this combination treatment 
as an option, it should be so regarded, especially for 
patients in whom therapy with sunitinib is expected 
to possibly be a cause of significant grade 3 and 4 
side effects.
Nonetheless, anti-angiogenic therapy is now the 
first and foremost choice in the initial management 
of metastatic r c c . Several new therapeutic options 
that are related to the mechanism of action of this 
agent are still under development, and the n c c n  guide-
lines still list—acceptably so—the inclusion of pa-
tients on clinical trial, especially if the trial permits 
comparison with the new standards of therapy. It is 
also worth mentioning that several groups have pub-
lished proposed guidelines on the management of side 
effects specifically related to v e g f r -t k i s—more spe-
cifically, hypothyroidism, fatigue, palmoplantar ery-
thema, and hypertension 12,13.
2.4  On Inhibitors of the Mammalian Target of 
Rapamycin
Mutations of the VHL gene occurring on both alleles 
provide an adequate explanation for the development 
of a targeted therapy based on a clonal anomaly that 
leads to an “oncogenic addiction.” However, other 
molecules involved in critical pathways of signal 
transduction seem to be particularly important in cell 
proliferation in r c c. The mammalian target of ra-
pamycin molecule is closely related to, among other 
things, pathways associated with angiogenesis 
through the v h l  complex 12.
Two molecules have been the object of trials and 
analyses in the context of guideline development: 
temsirolimus and everolimus. Unfortunately, estab-
lishing differences between these two molecules is 
difficult, because the trials studied very different 
populations in terms of patient characteristics and line 
of therapy. All guidelines propose the use of temsi-
rolimus in the first line for poor-risk patients. But the 
“poor risk” defined in this population is different than 
that used as a stratification factor in trials evaluating 
anti-angiogenic agents. Moreover, as indicated ear-
lier, the Canadian guidelines retained stratification 
for the v e g f r -t k i s, but accepted temsirolimus as an 
option for poor-risk patients.
Everolimus is the latest drug to be added to the 
list of therapeutic agents in r c c. First-line therapy has 
not been the subject of a trial, and in fact, most pa-
tients treated in further lines of therapy were in third, 
fourth, and fifth line with at least one v e g f r -t k i . Such 
a study was initiated when sunitinib was not ac-
cepted as a first-line standard. A true trial evaluating 
the efficacy of everolimus or another drug in the 
second-line setting after a v e g f r -t k i  has not yet been 
performed. The revised Canadian guidelines recom-
mend everolimus therapy as the standard after failure 
of a v e g f r -t k i ; however, that recommendation does 
not specifically imply therapy immediately after 
failure of the v e g f r -t k i . It is noteworthy that the n c c n  
does not list everolimus specifically, even though a 
clinical trial is listed as a consideration for patients 
with progression on a v e g f r -t k i .
2.5  On Periodic Review of Guidelines
The discovery that r c c is, in fact and contrary to 
previous data, a disease sensitive to targeted agents 
has made its therapy an area of intense and ongoing 
research activity. New results are expected to be 
presented at important oncology conferences in the 
coming years. Regarding existing guidelines, the 
review process is variable across groups. Intensifica-
tion of research and availability of the resulting data 
should be expected to bring new and more effective 
therapies, and guidelines will and should help the 
medical community to differentiate the value of these 
therapies for the community of patients with meta-
static r c c .
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